Emergent BioSolutions Reports Financial Results for Second Quarter 2023
- None.
- None.
- Reports Q2 2023 total revenues of
$338M , above the prior guidance range, net loss of$261M and adjusted EBITDA of$56M - Updates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues
GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
“Emergent has achieved a number of strategic milestones in 2023 that will help America be better prepared to face future public health threats and help to strengthen Emergent’s financial position,” said interim Chief Executive Officer Haywood Miller. “These achievements together with actions we announced earlier today will help ensure the sustainability of Emergent and its future growth.”
FINANCIAL HIGHLIGHTS (1)
Q2 2023 vs. Q2 2022
| ($ in millions, except per share amounts) | Q2 2023 | Q2 2022 | % Change |
| Total Revenues | |||
| Net Loss | * | ||
| Net Loss per Diluted Share | * | ||
| Adjusted Net Loss (2) | |||
| Adjusted Net Loss (2) per Diluted Share | |||
| Adjusted EBITDA (2) | * | ||
| Gross Margin % | |||
| Adjusted Gross Margin % (2) | |||
| * % change is greater than +/- | |||
Year to Date ("YTD") 2023 vs. YTD 2022
| ($ in millions, except per share amounts) | YTD 2023 | YTD 2022 | % Change |
| Total Revenues | (9)% | ||
| Net Loss | * | ||
| Net Loss per Diluted Share | * | ||
| Adjusted Net Loss (2) | * | ||
| Adjusted Loss (2) per Diluted Share | * | ||
| Adjusted EBITDA (2) | * | ||
| Gross Margin % | |||
| Adjusted Gross Margin % (2) | |||
| * % change is greater than +/- | |||
SELECT Q2 2023 AND OTHER RECENT BUSINESS UPDATES
- Announced CEO transition with the appointment of Haywood Miller as Interim CEO following the retirement of Robert G. Kramer
- Announced U.S. Food and Drug Administration (FDA) approval of CYFENDUSTM (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a two-dose anthrax vaccine for post-exposure prophylaxis use
- Finalized the sale of the travel health business to Bavarian Nordic for total consideration of up to
$380 million , including receipt of$270 million upfront; currently engaged in facilitating the transfer of assets, people and programs to Bavarian Nordic under a minimum six-month Transition Services Agreement - Completed amendment and maturity extension of the Company's existing senior secured credit facilities
- Awarded a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of EbangaTM (ansuvimab-zykl) product, a treatment for Ebola
Q2 2023 FINANCIAL PERFORMANCE (1)
Revenues
Beginning in 2023, the Company is revising the categories used in discussing product/service level revenues. The new categories are:
- Anthrax MCM — comprises potential contributions from CYFENDUSTM , previously known as AV7909, BioThrax, Anthrasil and raxibacumab
- NARCAN — comprises contributions from NARCAN Nasal Spray
- Smallpox MCM — comprises potential contributions from ACAM2000, VIGIV and Tembexa
- Other Products — comprises potential contributions from BAT, RSDL, Trobigard, Vaxchora and Vivotif
- CDMO — comprises service and lease revenues from the contract development and manufacturing business
| ($ in millions) | Q2 2023 | Q2 2022 | % Change | ||
| Product sales, net (3): | |||||
| (78)% | ||||
| |||||
| * | ||||
| (3)% | ||||
| Total product sales, net | |||||
| Contract development and manufacturing ("CDMO"): | |||||
| * | ||||
| * | ||||
| Total CDMO | * | ||||
| Contracts and grants | (10)% | ||||
| Total revenues | |||||
| * % change is greater than +/- | |||||
Product Sales, net
Anthrax MCM
For Q2 2023, revenues from Anthrax MCM decreased
NARCAN
For Q2 2023, revenues from NARCAN® (naloxone HCl) Nasal Spray increased
Smallpox MCM
For Q2 2023, revenues from Smallpox MCM increased
Other Products
For Q2 2023, revenues from other product sales decreased
CDMO
CDMO Services
For Q2 2023, revenues from contract development and manufacturing services increased
CDMO Leases
For Q2 2023, revenues from contract development and manufacturing leases increased
Contracts and Grants
For Q2 2023, revenues from contracts and grants decreased
Operating Expenses
| ($ in millions) | Q2 2023 | Q2 2022 | % Change | |
| Cost of product sales | ||||
| Cost of CDMO | (29)% | |||
| Impairment of long-lived assets | $— | NM | ||
| Research and development ("R&D") | (48)% | |||
| Selling, general and administrative | ||||
| Amortization of intangible assets | ||||
| Total operating expenses | * | |||
| * % change is greater than +/- | ||||
| NM - Not Meaningful | ||||
Cost of Product Sales
For Q2 2023, cost of product sales increased
Cost of CDMO
For Q2 2023, cost of CDMO decreased
Long-Lived Asset Impairment Charge
For Q2 2023, the Company recorded a non-cash impairment charge of
Prior to recording the impairment charge, the Company performed recoverability tests on the impacted asset groups within the CDMO reporting unit and concluded that the asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. The indicators for the impairment were related to the deterioration in performance and resulting downward revisions to our internal CDMO forecasts, including future expected cash flows, that took place during the preparation of our financial statements for the quarter ended June 30, 2023.
Research and Development (2)
For Q2 2023, R&D expenses decreased
Selling, General and Administrative
For Q2 2023, selling, general and administrative expenses increased
ADDITIONAL FINANCIAL INFORMATION (1)
Capital Expenditures
| ($ in millions) | Q2 2023 | Q2 2022 | % Change |
| Capital expenditures | (61)% | ||
| Capital expenditures as a % of total revenues | (900) bps |
For Q2 2023, gross capital expenditures decreased largely due to lower product development activities across the Company's facilities.
At-The-Market Equity Offering Program (ATM Program)
In Q2 2023, the Company initiated its "at-the-market" equity offering program (ATM Program). During the quarter ended June 30, 2023, the Company sold 1.1 million shares of its common stock under the ATM Program for gross proceeds of
Segment Information
The Company manages the business with a focus on two reportable segments: the Products segment, which includes the Anthrax MCM products, NARCAN products, Smallpox MCM products and Other products; and, the Services segment, which consists of CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but does not include inter-segment services. The Company does not allocate contracts and grants, R&D, SG&A, amortization of intangible assets, interest and other income (expense) or taxes to its evaluation of the performance of these segments.
| ($ in millions) | Products | Services | ||||
| Three Months Ended June 30, | Three Months Ended June 30, | |||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |
| Revenues | * | |||||
| Cost of sales | (29)% | |||||
| Less: Changes in fair value of contingent consideration | (69)% | $— | $— | NM | ||
| Less: Inventory step-up provision | $— | NM | $— | $— | NM | |
| Adjusted cost of sales ** | (29)% | |||||
| Gross margin *** | ||||||
| Gross margin % *** | (91)% | NM | ||||
| Adjusted gross margin **** | ||||||
| Adjusted gross margin % **** | (91)% | NM | ||||
| * % change is greater than +/- | ||||||
| ** Adjusted cost of sales, which is a non-GAAP financial measure, is calculated as cost of sales less restructuring costs, and other special items and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. See “Reconciliation of Non-GAAP Measures” for the reconciliation of this non-GAAP measure to the most closely related GAAP financial measure. | ||||||
| *** Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. | ||||||
| **** Adjusted gross margin, which is a non-GAAP financial measure, is calculated as revenues less Adjusted cost of sales. Adjusted gross margin %, which is a non-GAAP financial measure, is calculated as Adjusted gross margin divided by revenues. See “Reconciliation of Non-GAAP Measures” for the reconciliation of these non-GAAP measures to the most closely related GAAP financial measures. | ||||||
| NM - Not Meaningful | ||||||
For the three months ended June 30, 2023, Product gross margin and Product adjusted gross margin increased
For the three months ended June 30, 2023, Services gross margin increased
| ($ in millions) | Products | Services | ||||
| Six Months Ended June 30, | Six Months Ended June 30, | |||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |
| Revenues | (6)% | (25)% | ||||
| Cost of sales | (30)% | |||||
| Less: Changes in fair value of contingent consideration | $— | $— | NM | |||
| Less: Inventory step-up provision | $— | NM | $— | $— | NM | |
| Less: Restructuring costs | $— | NM | $— | $— | NM | |
| Adjusted cost of sales ** | (30)% | |||||
| Gross margin *** | (31)% | |||||
| Gross margin % *** | (144)% | (162)% | ||||
| Adjusted gross margin **** | (30)% | |||||
| Adjusted gross margin % **** | (144)% | (162 )% | ||||
| * % change is greater than +/- | ||||||
| ** Adjusted cost of sales, which is a non-GAAP financial measure, is calculated as cost of sales less restructuring costs, and other special items and non-cash items related to changes in fair value of contingent consideration and inventory step-up provision. See “Reconciliation of Non-GAAP Measures” for the reconciliation of this non-GAAP measure to the most closely related GAAP financial measure. | ||||||
| *** Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. | ||||||
| **** Adjusted gross margin, which is a non-GAAP financial measure, is calculated as revenues less Adjusted cost of sales. Adjusted gross margin %, which is a non-GAAP financial measure, is calculated as Adjusted gross margin divided by revenues. See “Reconciliation of Non-GAAP Measures” for the reconciliation of these non-GAAP measures to the most closely related GAAP financial measures. | ||||||
| NM - Not Meaningful | ||||||
For the six months ended June 30, 2023, Product gross margin and Product adjusted gross margin decreased
For the six months ended June 30, 2023, Services gross margin increased
2023 FINANCIAL FORECAST
The Company provides the following updated financial forecast for the full year 2023 and initial forecast for total revenues for Q3 2023, in both instances reflecting management's expectations based on the most current information available and taking into account the actual performance in Q1 and Q2 2023.
Full Year 2023
| METRIC ($ in millions) | Updated Range (as of 08/08/23) | Action | Previous Range (as of 05/09/23) |
| Total Revenues | REVISED | ||
| Net Loss | REVISED | ||
| Adjusted Net Loss (2) | REVISED | ||
| Adjusted EBITDA (2) | REVISED | ||
| Adjusted Gross Margin % (2) | REVISED | ||
| Product/Service Level Revenue | |||
| REVISED | ||
| REVISED | ||
| REVISED | ||
| REVISED | ||
| REVISED | ||
The updated 2023 financial forecast as of 08/08/2023 reflects the following key considerations.
- Total Revenues — Revised, reflecting ongoing strength in NARCAN, offset by reduced near term expectations across other products and services.
- Anthrax MCM — Revised, reflecting reduced short-term CYFENDUS volume following FDA-approval as procurement transitions from BARDA to the Strategic National Stockpile.
- NARCAN — Revised, reflecting continued robust demand from the US Public Interest channel and Canada.
- Smallpox MCM — Revised, reflecting recent USG guidance that next procurement of TEMBEXA is deferred to future periods.
- Other Products — Revised, reflecting reduced expectations for Trobigard.
- CDMO — Revised, reflecting lower anticipated sales at the Camden site.
- Adjusted Net Loss and Adjusted EBITDA — Revised, reflecting lower total revenues partially offset by the impact of cost actions announced on August 8, 2023.
Q3 2023
| METRIC ($ in millions) | Initial Range (as of 08/08/23) |
| Total Revenues |
FOOTNOTES
(1) All financial information incorporated within this release is unaudited.
(2) See "Reconciliation of Non-GAAP Measures" and the reconciliation tables for the definitions and reconciliations of these non-GAAP financial measures to the most closely related GAAP financial measures.
(3) Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with U.S. generally accepted accounting principles.
CONFERENCE CALL, PRESENTATION SUPPLEMENT AND WEBCAST INFORMATION
Company management will host a conference call at 5:00 pm eastern time today, August 8, 2023, to discuss these financial results. The conference call and presentation supplement can be accessed from the Company's website or through the following:
By phone
Advance registration is required.
Visit https://register.vevent.com/register/BIc94fd6cf2c104ae9a17e49a183e9a781 to register and receive an email with the dial-in number, passcode and registrant ID.
By webcast
Visit https://edge.media-server.com/mmc/p/bqhs3ww3.
A replay of the call can be accessed from the Emergent website.
ABOUT EMERGENT BIOSOLUTIONS INC.
At Emergent, our mission is to protect and enhance life. We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For over 20 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our website and follow us on LinkedIn, Twitter, and Instagram.
RECONCILIATION OF NON-GAAP MEASURES
This press release contains financial measures (Adjusted Net Loss, Adjusted Net Loss per Diluted Shares, Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization), Adjusted Gross Margin, Adjusted Gross Margin %, Adjusted Revenues, Adjusted Cost of Sales and Adjusted Research and Development Expenses) that are considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. For its non-GAAP measures, the Company adjusts for specified items that can be highly variable or difficult to predict, or reflect the non-cash impact of charges or accounting changes. As needed, such adjustments are tax effected utilizing the federal statutory tax rate for the U.S., except for changes in the fair value of contingent consideration as the vast majority is non-deductible for tax purposes. The Company views these non-GAAP financial measures as a means to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the Company’s business. For more information on these non-GAAP financial measures, please see the tables captioned "Reconciliation of Net Loss and Net Loss per Diluted Share to Adjusted Net Loss and Adjusted Net Loss per Diluted Share," "Reconciliation of Net Loss to Adjusted EBITDA," "Reconciliation of Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin %," and "Reconciliation of Research and Development Expenses to Adjusted Research and Development Expenses" included at the end of this release.
The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or our business strategy, future operations, future financial position, future revenues and earnings, statements regarding the expected timing for implementation of its restructuring activities, its total and cash cost, our ability to achieve the objectives of the restructuring, including our future results, projected costs, prospects, plans and objectives of management and the ongoing impact of the COVID-19 pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasures, including CYFENDUSTM (Anthrax Vaccine Adsorbed (AVA), Adjuvanted), BioThrax® (Anthrax Vaccine Adsorbed) and ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), among others, as well as contracts related to development of medical countermeasures; our ability to meet our commitments to quality and compliance in all of our manufacturing operations; our ability to negotiate additional USG procurement or follow-on contracts for our medical countermeasures products that have expired or will be expiring; the commercial availability, including the timing of availability, of over-the-counter NARCAN® (naloxone HCI) Nasal Spray; the impact of the generic marketplace on NARCAN® (naloxone HCI) Nasal Spray and future NARCAN sales; our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries; our ability to provide CDMO services for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines; the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations; our ability to negotiate new CDMO contracts and the negotiation of further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing CDMO contracts; our ability to collect reimbursement for raw materials and payment of services fees from our CDMO customers; the results of pending shareholder litigation and government investigations and their potential impact on our business; our ability to comply with the operating and financial covenants required by our senior secured credit facilities and the amended and restated credit agreement relating to such facilities, and our
| Investor Contact Rich Lindahl Executive Vice President, Chief Financial Officer lindahlr@ebsi.com | Media Contact Matt Hartwig Senior Director, Media Relations mediarelations@ebsi.com |
Emergent BioSolutions Inc.
Consolidated Balance Sheets
(unaudited, in millions, except per share data)
| June 30, | December 31, | ||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 88.6 | $ | 642.6 | |||
| Accounts receivable, net | 290.1 | 158.4 | |||||
| Inventories, net | 354.3 | 351.8 | |||||
| Prepaid expenses and other current assets | 44.7 | 57.9 | |||||
| Total current assets | 777.7 | 1,210.7 | |||||
| Property, plant and equipment, net | 395.5 | 817.6 | |||||
| Intangible assets, net | 592.8 | 728.8 | |||||
| Goodwill | 218.2 | 218.2 | |||||
| Other assets | 194.6 | 191.3 | |||||
| Total assets | $ | 2,178.8 | $ | 3,166.6 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 108.3 | $ | 103.5 | |||
| Accrued expenses | 31.2 | 34.9 | |||||
| Accrued compensation | 69.6 | 88.3 | |||||
| Debt, current portion | 455.2 | 957.3 | |||||
| Other current liabilities | 28.9 | 45.9 | |||||
| Total current liabilities | 693.2 | 1,229.9 | |||||
| Debt, net of current portion | 448.0 | 448.5 | |||||
| Deferred tax liability | 57.9 | 71.8 | |||||
| Other liabilities | 23.4 | 33.4 | |||||
| Total liabilities | $ | 1,222.5 | $ | 1,783.6 | |||
| Stockholders’ equity: | |||||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 0.1 | 0.1 | |||||
| Treasury stock, at cost, 5.6 and 5.6 common shares, respectively | (227.7 | ) | (227.7 | ) | |||
| Additional paid-in capital | 895.8 | 873.5 | |||||
| Accumulated other comprehensive income (loss), net | (1.6 | ) | 3.1 | ||||
| Retained earnings | 289.7 | 734.0 | |||||
| Total stockholders’ equity | $ | 956.3 | $ | 1,383.0 | |||
| Total liabilities and stockholders’ equity | $ | 2,178.8 | $ | 3,166.6 | |||
Emergent BioSolutions Inc.
Consolidated Statements of Operations
(unaudited, in millions, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues: | |||||||||||||||
| Product sales, net | $ | 302.2 | $ | 237.2 | $ | 445.6 | $ | 474.3 | |||||||
| Contract development and manufacturing ("CDMO"): | |||||||||||||||
| Services | 26.4 | 2.7 | 39.8 | 54.5 | |||||||||||
| Leases | 2.7 | (4.5 | ) | 4.5 | 4.5 | ||||||||||
| Total CDMO revenues | 29.1 | (1.8 | ) | 44.3 | 59.0 | ||||||||||
| Contracts and grants | 6.6 | 7.3 | 13.1 | 16.9 | |||||||||||
| Total revenues | 337.9 | 242.7 | 503.0 | 550.2 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of product sales | 134.9 | 91.0 | 237.8 | 171.3 | |||||||||||
| Cost of CDMO | 55.7 | 78.8 | 107.9 | 154.4 | |||||||||||
| Impairment of long-lived assets | 306.7 | — | 306.7 | — | |||||||||||
| Research and development | 26.0 | 49.8 | 66.6 | 96.2 | |||||||||||
| Selling, general and administrative | 91.4 | 81.1 | 191.9 | 165.9 | |||||||||||
| Amortization of intangible assets | 16.1 | 14.0 | 33.1 | 28.0 | |||||||||||
| Total operating expenses | 630.8 | 314.7 | 944.0 | 615.8 | |||||||||||
| Loss from operations | (292.9 | ) | (72.0 | ) | (441.0 | ) | (65.6 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest expense | (28.6 | ) | (7.8 | ) | (46.5 | ) | (16.0 | ) | |||||||
| Gain on sale of business | 74.9 | — | 74.9 | — | |||||||||||
| Other, net | (3.6 | ) | (3.0 | ) | 1.3 | (5.0 | ) | ||||||||
| Total other income (expense), net | 42.7 | (10.8 | ) | 29.7 | (21.0 | ) | |||||||||
| Loss before income taxes | (250.2 | ) | (82.8 | ) | (411.3 | ) | (86.6 | ) | |||||||
| Income tax provision (benefit) | 11.1 | (26.4 | ) | 33.0 | (26.5 | ) | |||||||||
| Net loss | $ | (261.3 | ) | $ | (56.4 | ) | $ | (444.3 | ) | $ | (60.1 | ) | |||
| Net loss per common share | |||||||||||||||
| Basic | $ | (5.15 | ) | $ | (1.13 | ) | $ | (8.80 | ) | $ | (1.19 | ) | |||
| Diluted | $ | (5.15 | ) | $ | (1.13 | ) | $ | (8.80 | ) | $ | (1.19 | ) | |||
| Shares used in computing net loss per share | |||||||||||||||
| Basic | 50.7 | 50.0 | 50.5 | 50.3 | |||||||||||
| Diluted | 50.7 | 50.0 | 50.5 | 50.3 | |||||||||||
Emergent BioSolutions Inc.
Consolidated Statements of Cash Flows
(unaudited, in millions, except per share data)
| Six Months Ended June 30, | |||||||
| 2023 | 2022 | ||||||
| Operating Activities | |||||||
| Net loss | $ | (444.3 | ) | $ | (60.1 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock-based compensation expense | 15.1 | 22.2 | |||||
| Long-term incentive plan expense | 2.4 | — | |||||
| Depreciation and amortization | 67.5 | 75.4 | |||||
| Change in fair value of contingent obligations, net | 1.9 | 1.8 | |||||
| Amortization of deferred financing costs | 9.9 | 2.0 | |||||
| Deferred income taxes | (10.2 | ) | 2.6 | ||||
| Gain on sale of travel health business | (74.9 | ) | — | ||||
| Impairment of long-lived assets | 306.7 | — | |||||
| Other | 9.5 | 2.2 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (130.6 | ) | 97.7 | ||||
| Inventories | (23.8 | ) | (75.5 | ) | |||
| Prepaid expenses and other assets | (17.8 | ) | (19.4 | ) | |||
| Accounts payable | 10.9 | (7.6 | ) | ||||
| Accrued expenses and other liabilities | (13.8 | ) | (36.4 | ) | |||
| Accrued compensation | (13.4 | ) | (14.1 | ) | |||
| Income taxes receivable and payable, net | 14.2 | (46.4 | ) | ||||
| Contract liabilities | (7.7 | ) | 2.7 | ||||
| Net cash used in operating activities | (298.4 | ) | (52.9 | ) | |||
| Investing Activities | |||||||
| Purchases of property, plant and equipment | (27.6 | ) | (64.3 | ) | |||
| Proceeds from sale of travel health business, net | 270.2 | — | |||||
| Net cash provided by (used in) investing activities | 242.6 | (64.3 | ) | ||||
| Financing Activities | |||||||
| Purchases of treasury stock | — | (81.9 | ) | ||||
| Principal payments on revolving credit facility | (347.8 | ) | — | ||||
| Principal payments on term loan facility | (156.8 | ) | (16.9 | ) | |||
| Proceeds from stock-based compensation activity | 1.3 | 3.0 | |||||
| Taxes paid for stock-based compensation activity | (2.3 | ) | (5.4 | ) | |||
| Proceeds from at-the-market sale of stock, net of commissions and expenses | 8.2 | — | |||||
| Net cash used in financing activities: | (497.4 | ) | (101.2 | ) | |||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (0.8 | ) | 0.4 | ||||
| Net change in cash, cash equivalents and restricted cash | (554.0 | ) | (218.0 | ) | |||
| Cash, cash equivalents and restricted cash, beginning of period | 642.6 | 576.3 | |||||
| Cash, cash equivalents and restricted cash, end of period | $ | 88.6 | $ | 358.3 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Cash paid for interest | $ | 38.8 | $ | 14.8 | |||
| Cash paid for income taxes | $ | 26.9 | $ | 20.0 | |||
| Supplemental information on non-cash investing and financing activities: | |||||||
| Purchases of property, plant and equipment unpaid at period end | $ | 7.7 | $ | 7.3 | |||
Reconciliation of Net Loss and Net Loss per Diluted Share to Adjusted Net Loss and Adjusted Net Loss per Diluted Share(1)
| ($ in millions, except per share value) | Three Months Ended June 30, | ||
| 2023 | 2022 | Source | |
| Net loss | |||
| Adjustments: | |||
| Non-cash amortization charges | 25.0 | 14.9 | Intangible Asset (IA) Amortization, Other Income |
| Changes in fair value of contingent consideration | 0.4 | 1.3 | Product COGS |
| Impairment of long-lived assets | 306.7 | — | Impairment of long-lived assets |
| Restructuring costs | (0.1) | — | Product COGS, SG&A and R&D |
| Severance Charge | 4.2 | — | SG&A |
| Inventory Step-up provision | 1.9 | — | Product COGS |
| Divestiture related costs | 1.7 | — | SG&A |
| Exit and disposal costs | 6.1 | — | Other income (expense) |
| Acquisition-related costs (transaction & integration) | 0.1 | 0.8 | SG&A |
| Gain on sale of business | (74.9) | — | Other income (expense) |
| Tax effect | (63.3) | (3.4) | |
| Total adjustments: | 207.8 | ||
| Adjusted net loss | (53.5) | ( | |
| Net loss per diluted share | |||
| Adjustments: | |||
| Non-cash amortization charges | 0.49 | 0.29 | IA Amortization, Other Income |
| Changes in fair value of contingent consideration | 0.01 | 0.03 | Product COGS |
| Impairment of long-lived assets | 6.05 | — | Impairment of long-lived assets |
| Severance charge | 0.08 | — | SG&A |
| Restructuring costs | — | — | Product COGS, SG&A and R&D |
| Inventory step-up provision | 0.04 | — | Product COGS |
| Divestiture related costs | 0.03 | — | SG&A |
| Exit and disposal costs | 0.12 | — | Other income (expense) |
| Acquisition-related costs (transaction & integration) | — | 0.02 | SG&A |
| Gain on sale of business | (1.48) | — | Other income (expense) |
| Tax effect | (1.25) | (0.07) | |
| Total adjustments: | |||
| Adjusted net loss per diluted share | ( | ||
| Diluted shares used in computing adjusted net loss per diluted share | 50.7 | 50.0 | |
| ($ in millions, except per share value) | Six Months Ended June 30, | ||
| 2023 | 2022 | Source | |
| Net loss | |||
| Adjustments: | |||
| Non-cash amortization charges | 43.0 | 30.0 | Intangible Asset (IA) Amortization, Other Income |
| Changes in fair value of contingent consideration | 1.9 | 1.8 | Product COGS |
| Impairment of long-lived assets | 306.7 | — | Impairment of long-lived assets |
| Severance charge | 4.2 | — | SG&A |
| Restructuring costs | 9.6 | — | Product COGS, SG&A and R&D |
| Inventory step-up provision | 1.9 | — | Product COGS |
| Divestiture related costs | 2.7 | — | SG&A |
| Exit and disposal costs | 6.1 | — | Other income (expense) |
| Acquisition-related costs (transaction & integration) | 0.2 | 1.2 | SG&A |
| Gain on sale of business | (74.9) | — | Other income (expense) |
| Tax effect | (69.4) | (6.6) | |
| Total adjustments: | |||
| Adjusted net loss | ( | ||
| Net loss per diluted share | |||
| Adjustments: | |||
| Non-cash amortization charges | 0.85 | 0.60 | IA Amortization, Other Income |
| Changes in fair value of contingent consideration | 0.04 | 0.04 | Product COGS |
| Impairment of long-lived assets | 6.07 | — | Impairment of long-lived assets |
| Severance charge | 0.08 | — | SG&A |
| Restructuring costs | 0.19 | — | Product COGS, SG&A and R&D |
| Inventory step-up provision | 0.04 | — | Product COGS |
| Divestiture related costs | 0.05 | — | SG&A |
| Exit and disposal costs | 0.12 | — | Other income (expense) |
| Acquisition-related costs (transaction & integration) | — | 0.02 | SG&A |
| Gain on sale of business | (1.48) | — | Other income (expense) |
| Tax effect | (1.37) | (0.14) | |
| Total adjustments: | |||
| Adjusted net loss per diluted share | ( | ||
| Diluted shares used in computing adjusted net loss per diluted share | 50.5 | 50.3 | |
| ($ in millions) | 2023 Revised Full Year Forecast | Source | |
| Net loss | |||
| Adjustments: | |||
| Non-cash amortization charges | IA Amortization Other Income | ||
| Impairment of long-lived assets | Impairment of long-lived assets | ||
| Inventory step-up provision | Product COGS | ||
| Changes in fair value of contingent consideration | Product COGS | ||
| Severance and restructuring costs | Product COGS, SG&A and R&D | ||
| Divestiture related costs | SG&A | ||
| Exit and disposal costs | Other income (expense) | ||
| Acquisition-related costs (transaction & integration) | SG&A | ||
| Gain on sale of business | Other income (expense) | ||
| Tax effect | |||
| Total adjustments: | |||
| Adjusted net loss | |||
Reconciliation of Net Loss to Adjusted EBITDA (1)
| ($ in millions) | Three Months Ended June 30, | |
| 2023 | 2022 | |
| Net loss | ||
| Adjustments: | ||
| Depreciation & amortization | 32.9 | 44.5 |
| Income taxes | 11.1 | (26.4) |
| Total interest expense, net | 27.1 | 7.4 |
| Impairment of long-lived assets | 306.7 | — |
| Inventory step-up provision | 1.9 | — |
| Changes in fair value of contingent consideration | 0.4 | 1.3 |
| Severance charge | 4.2 | — |
| Restructuring costs | (0.1) | — |
| Divestiture related costs | 1.7 | — |
| Exit and disposal costs | 6.1 | — |
| Acquisition-related costs (transaction & integration) | 0.1 | 0.8 |
| Gain on sale of business | (74.9) | — |
| Total adjustments | ||
| Adjusted EBITDA | ||
| ($ in millions) | Six Months Ended June 30, | |
| 2023 | 2022 | |
| Net loss | ||
| Adjustments: | ||
| Depreciation & amortization | 67.5 | 75.4 |
| Income taxes | 33.0 | (26.5) |
| Total interest expense, net | 40.5 | 15.4 |
| Impairment of long-lived assets | 306.7 | — |
| Inventory step-up provision | 1.9 | — |
| Changes in fair value of contingent consideration | 1.9 | 1.8 |
| Severance charge | 4.2 | — |
| Restructuring costs | 9.6 | — |
| Divestiture related costs | 2.7 | — |
| Exit and disposal costs | 6.1 | — |
| Acquisition-related costs (transaction & integration) | 0.2 | 1.2 |
| Gain on sale of business | (74.9) | — |
| Total adjustments | ||
| Adjusted EBITDA | ||
| ($ in millions) | 2023 Revised Full Year Forecast |
| Net loss | |
| Adjustments: | |
| Depreciation & amortization | |
| Income Taxes | |
| Total interest expense, net | |
| Impairment of long-lived assets | |
| Inventory step-up provision | |
| Changes in fair value of contingent consideration | |
| Severance and restructuring costs | |
| Divestiture related costs | |
| Exit and disposal costs | |
| Acquisition-related costs (transaction & integration) | |
| Gain on sale of business | |
| Total adjustments | 515 |
| Adjusted EBITDA |
Reconciliation of Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin % (1)
| ($ in millions) | Three Months Ended June 30, | |
| 2023 | 2022 | |
| Total revenues | ||
| Contract and grants revenues | ||
| Adjusted revenues | ||
| Cost of product sales | ||
| Cost of contract development and manufacturing | ||
| Cost of product sales and cost of contract development and manufacturing services ("COGS") | ||
| Less: Changes in fair value of contingent consideration | ||
| Less: Inventory step-up provision | $— | |
| Adjusted COGS | ||
| Gross margin (adjusted revenues minus COGS) | ||
| Gross margin % (gross margin divided by adjusted revenues) | ||
| Adjusted gross margin (adjusted revenues minus adjusted COGS) | ||
| Adjusted gross margin % (adjusted gross margin divided by adjusted revenues) | ||
| ($ in millions) | Six Months Ended June 30, | |
| 2023 | 2022 | |
| Total revenues | ||
| Contract and grants revenues | ||
| Adjusted revenues | ||
| Cost of product sales | ||
| Cost of contract development and manufacturing | ||
| Cost of product sales and cost of contract development and manufacturing services ("COGS") | ||
| Less: Changes in fair value of contingent consideration | ||
| Less: Inventory step-up provision | $— | |
| Less: Restructuring costs | $— | |
| Adjusted COGS | ||
| Gross margin (adjusted revenues minus COGS) | ||
| Gross margin % (gross margin divided by adjusted revenues) | ||
| Adjusted gross margin (adjusted revenues minus adjusted COGS) | ||
| Adjusted gross margin % (adjusted gross margin divided by adjusted revenues) | ||
| ($ in millions) | 2023 Revised Full Year Forecast | |
| Total Revenues | ||
| Contracts and Grants Revenues | ||
| Adjusted Revenues | ||
| COGS | ||
| Changes in fair value of contingent consideration and restructuring | ||
| Adjusted COGS | ||
| Gross margin (adjusted revenues minus COGS) | ||
| Gross margin % (gross margin divided by adjusted revenues) | ||
| Adjusted gross margin (adjusted revenues minus adjusted COGS) | ||
| Adjusted gross margin % (adjusted gross margin divided by adjusted revenues) | ||
Reconciliation of R&D Expenses and Adjusted R&D Expenses (1)
| ($ in millions) | Three Months Ended June 30, | |
| 2023 | 2022 | |
| R&D expenses | ||
| Adjustments: | ||
| Contracts and grants revenue | ||
| Adjusted R&D expenses | ||
| Adjusted Revenue (Total Revenue less Contracts and Grants Revenue) | ||
| Adjusted R&D as % of Adjusted Revenue | ||
| ($ in millions) | Six Months Ended June 30, | |
| 2023 | 2022 | |
| R&D expenses | ||
| Adjustments: | ||
| Contracts and grants revenue | ||
| Adjusted R&D expenses | ||
| Adjusted Revenue (Total Revenue less Contracts and Grants Revenue) | ||
| Adjusted R&D as % of Adjusted Revenue | ||
FAQ
What were Emergent BioSolutions' Q2 2023 financial results?
What is Emergent BioSolutions' updated guidance for FY 2023?
What steps has Emergent BioSolutions announced to reduce investment in its CDMO business?
